These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24911152)

  • 1. Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.
    Hansen FH; Skjørringe T; Yasmeen S; Arends NV; Sahai MA; Erreger K; Andreassen TF; Holy M; Hamilton PJ; Neergheen V; Karlsborg M; Newman AH; Pope S; Heales SJ; Friberg L; Law I; Pinborg LH; Sitte HH; Loland C; Shi L; Weinstein H; Galli A; Hjermind LE; Møller LB; Gether U
    J Clin Invest; 2014 Jul; 124(7):3107-20. PubMed ID: 24911152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying dominant-negative actions of a dopamine transporter variant in patients with parkinsonism and neuropsychiatric disease.
    Herborg F; Jensen KL; Tolstoy S; Arends NV; Posselt LP; Shekar A; Aguilar JI; Lund VK; Erreger K; Rickhag M; Lycas MD; Lonsdale MN; Rahbek-Clemmensen T; Sørensen AT; Newman AH; Løkkegaard A; Kjærulff O; Werge T; ; Møller LB; Matthies HJ; Galli A; Hjermind LE; Gether U
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.
    Herborg F; Andreassen TF; Berlin F; Loland CJ; Gether U
    J Biol Chem; 2018 May; 293(19):7250-7262. PubMed ID: 29559554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia.
    Kurian MA; Zhen J; Cheng SY; Li Y; Mordekar SR; Jardine P; Morgan NV; Meyer E; Tee L; Pasha S; Wassmer E; Heales SJ; Gissen P; Reith ME; Maher ER
    J Clin Invest; 2009 Jun; 119(6):1595-603. PubMed ID: 19478460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder.
    Krause J
    Expert Rev Neurother; 2008 Apr; 8(4):611-25. PubMed ID: 18416663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single Quantum Dot Imaging Reveals PKCβ-Dependent Alterations in Membrane Diffusion and Clustering of an Attention-Deficit Hyperactivity Disorder/Autism/Bipolar Disorder-Associated Dopamine Transporter Variant.
    Thal LB; Tomlinson ID; Quinlan MA; Kovtun O; Blakely RD; Rosenthal SJ
    ACS Chem Neurosci; 2019 Jan; 10(1):460-471. PubMed ID: 30153408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADHD and the dopamine transporter: are there reasons to pay attention?
    Mazei-Robinson MS; Blakely RD
    Handb Exp Pharmacol; 2006; (175):373-415. PubMed ID: 16722244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation.
    Sakrikar D; Mazei-Robison MS; Mergy MA; Richtand NW; Han Q; Hamilton PJ; Bowton E; Galli A; Veenstra-Vanderweele J; Gill M; Blakely RD
    J Neurosci; 2012 Apr; 32(16):5385-97. PubMed ID: 22514303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infantile parkinsonism-dystonia: a dopamine "transportopathy".
    Blackstone C
    J Clin Invest; 2009 Jun; 119(6):1455-8. PubMed ID: 19504720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.
    Szobot CM; Shih MC; Schaefer T; Júnior N; Hoexter MQ; Fu YK; Pechansky F; Bressan RA; Rohde LA
    Neuroimage; 2008 Apr; 40(3):1195-201. PubMed ID: 18282769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-quantum-dot tracking reveals altered membrane dynamics of an attention-deficit/hyperactivity-disorder-derived dopamine transporter coding variant.
    Kovtun O; Sakrikar D; Tomlinson ID; Chang JC; Arzeta-Ferrer X; Blakely RD; Rosenthal SJ
    ACS Chem Neurosci; 2015 Apr; 6(4):526-34. PubMed ID: 25747272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is dopamine transporter-mediated dopaminergic signaling in the retina a noninvasive biomarker for attention-deficit/ hyperactivity disorder? A study in a novel dopamine transporter variant Val559 transgenic mouse model.
    Dai H; Jackson CR; Davis GL; Blakely RD; McMahon DG
    J Neurodev Disord; 2017 Dec; 9(1):38. PubMed ID: 29281965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Action of Zn2+ on the Transport Cycle of the Dopamine Transporter.
    Li Y; Hasenhuetl PS; Schicker K; Sitte HH; Freissmuth M; Sandtner W
    J Biol Chem; 2015 Dec; 290(52):31069-76. PubMed ID: 26504078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability.
    Santoro L; Breedveld GJ; Manganelli F; Iodice R; Pisciotta C; Nolano M; Punzo F; Quarantelli M; Pappatà S; Di Fonzo A; Oostra BA; Bonifati V
    Neurogenetics; 2011 Feb; 12(1):33-9. PubMed ID: 20853184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment.
    Dresel S; Krause J; Krause KH; LaFougere C; Brinkbäumer K; Kung HF; Hahn K; Tatsch K
    Eur J Nucl Med; 2000 Oct; 27(10):1518-24. PubMed ID: 11083541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood.
    Ng J; Zhen J; Meyer E; Erreger K; Li Y; Kakar N; Ahmad J; Thiele H; Kubisch C; Rider NL; Morton DH; Strauss KA; Puffenberger EG; D'Agnano D; Anikster Y; Carducci C; Hyland K; Rotstein M; Leuzzi V; Borck G; Reith ME; Kurian MA
    Brain; 2014 Apr; 137(Pt 4):1107-19. PubMed ID: 24613933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
    Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
    Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic imaging study with [Tc-
    Akay AP; Kaya GÇ; Kose S; Yazıcıoğlu ÇE; Erkuran HÖ; Güney SA; Oğuz K; Keskin D; Baykara B; Emiroğlu Nİ; Eren MŞ; Kızıldağ S; Ertay T; Özsoylu D; Miral S; Durak H; Gönül AS; Rohde LA
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():294-300. PubMed ID: 29684537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yang HJ; Park SH; Seo M; Weon YC; Kim Y
    Neurotoxicology; 2018 Jan; 64():78-84. PubMed ID: 28259768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.